AFM13 in combination with cord blood-derived NK cells is now under assessment in a phase I/II trial for patients with recurrent or refractory CD30+ Hodgkin or non-Hodgkin lymphoma (NCT04074746). The gene discussed is TNFRSF8; the disease is non-Hodgkin lymphoma.